Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold

Autolus Therapeutics plc

2025-Q2 EPS reported -$0.44 vs consensus -$0.24 ▼ miss (-83.0%)

Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.
UK MHRA (Apr 25) and EC (Jul 17) conditional approvals granted for AUCATZYL in r/r B-ALL.
NICE preliminary ACD recommended against funding; EU launch paused, no sales expected in 2025-2026.
Cash $454.3M (Jun 30 vs $588.0M Dec 31); net loss $47.9M (Q2 2025) vs $58.3M (Q2 2024).
Pipeline: obe-cel Phase 2 LN trial and Phase 1 MS trial first patient dosing by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.